This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	NEDD8 activating enzyme (NAE)	<p>Studies in cell culture and in mice suggest that inhibiting NAE could help treat cancer. In cultured human colon cancer cells, Millennium Pharmaceuticals Inc.'s NAE inhibitor MLN4294, an N⁶-benzyl adenosine derivative, disregulated DNA replication and caused cell death. In mice with colon and lung xenograft tumors, MLN4294 decreased tumor volume with no significant side effects.</p> <p>Millennium, a unit of Takeda Pharmaceutical Co. Ltd., is running Phase I studies of MLN4294 to treat lymphoma, multiple myeloma (MM) and advanced nonhematological malignancies.</p> <p>SciBX 2(15); doi:10.1038/scibx.2009.615 Published online April 16, 2009</p>	Patented; unavailable for licensing	<p>Soucy, T. <i>et al. Nature</i>; published online April 8, 2009; doi:10.1038/nature07884</p> <p>Contact: Teresa Soucy, Millennium Pharmaceuticals Inc., Cambridge, Mass. e-mail: teresa.soucy@mpi.com</p>